NCT00724386已完成1 期
A Phase I Study of Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine With Filgrastim Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- dose-limiting toxicity
研究概览
简要总结
The goal of this study is to determine the feasibility based on toxicity and response rate of giving paclitaxel weekly with concomitant every-other week radiotherapy to limit skin toxicity. This study will also seek to determine the maximally tolerated dose of Navelbine added to this combination when followed by Filgrastim and the dose-limiting toxicities of this regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed adenocarcinoma of the male or female breast (male or female) with gross, uncontrolled, unresectable breast and/or chest wall disease including:
- •patients with locally advanced unresectable stage IIIa or IIIb;
- •patients with locally recurrent (including locoregional lymph nodes) disease for which curative surgery is not thought possible
- •patients with metastatic disease AND uncontrolled locoregional disease are eligible.
- •Prior chemotherapy allowed, except for nitrosoureas and mitomycin chemotherapy or high dose chemotherapy with marrow or stem cell rescue.
- •Prior palliative radiation to sites of metastases allowed (i.e. bone, brain, lung)
- •4 weeks since any prior treatments (excluding hormonal therapy). Concurrent hormonal therapy is not allowed.
- •Aged 18 years or older
- •CALGB performance status of 0 - 2
- •Life expectance of at least 12 weeks
- •Initial Laboratory Data:
- •ANC Count > 1500/mm3
- •Platelet Count > 100,000/mm3
- •Creatine ≤ 2.0 mg/dl
- •Bilirubin ≤ 1.5 mg/dl
- •ALT (SGPT) ≤ 3 times the upper limit of normal
- •Signed informed consent
排除标准
- •Prior breast or chest wall radiation is not allowed unless the proposed site radiation port does not overlap with prior ports
- •Subjects must not be pregnant (females able to have children must have negative pregnancy test and agree to use adequate contraception)
- •Patients with a documented hypersensitivity to E.coli derived proteins are excluded.
- •No other serious medical condition such as uncontrolled infection that in the opinion of the investigators places patient at undue risk for study treatment
结局指标
主要结局
dose-limiting toxicity
时间窗: 4 weeks
feasibility of administering study therapy to limit skin toxicity
时间窗: 4 weeks
次要结局
- response(14 weeks)
- time to progression
- overall survival
- Bcl-2 detection by immunohistochemistry(14 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
CCRT With Itraconazole in Locally Advanced Squamous Esophageal CancerEsophageal NeoplasmEsophageal DiseasesEsophageal Squamous Cell CarcinomaNCT04481100Hangzhou Cancer Hospital38
撤回
1 期
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck CancersHead and Neck CancerSquamous Cell Carcinoma of Head and NeckOral Cavity Squamous Cell CarcinomaOral Cavity CancerOropharynx CancerOropharynx Squamous Cell CarcinomaLarynx CancerPharynx CancerHypopharynx CancerHypopharynx Squamous Cell CarcinomaNCT04892875Jennifer Choe
招募中
1 期
Feasibility study of concurrent chemoradiotherapy with docetaxel and cisplatin for head and neck cancer in the elderly or mild renal dysfunction -Multicenter studyhead and neck cancerJPRN-UMIN000009270Department of Otolaryngology-Head and Neck Surgery, Osaka University School of Medicine30
终止
3 期
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung CancerNon-small Cell Lung CarcinomaNCT00633568European Lung Cancer Working Party125
已完成
1 期
A phase I/II study of concurrent chemoradiotherapy (RT-DeVIC) for newly-diagnosed, localized nasal NK/T-cell lymphoma (JCOG0211-DI)extranodal NK/T-cell lymphoma, nasal typeJPRN-UMIN000007842Japan Clinical Oncology Group (JCOG)33